Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck/Schering Vytorin Launch Could Be Aided By New Cholesterol Guidelines

Executive Summary

Revised cholesterol treatment guidelines could result in increased use of combination lipid-lowering therapies as Merck/Schering-Plough's Vytorin enters the market
Advertisement

Related Content

NICE Guidance Expected To Add 1.4 Million To Roster Of Statin Users
Rising Drug Use Stems From Changes In Clinical Guidelines – PhRMA Report
High-Dose Lipitor Is As Safe As Lower Doses, Pfizer Analysis Finds
High-Dose Statins IDEAL For Use In High-Risk Patients, Study Suggests
Statins Would Have Special Status Under Health Savings Accounts
Vytorin Price Will Be Key To Impact In Cholesterol Market, AstraZeneca Says
Schering/Merck Ready For Vytorin; Lipid Market Growth Returns
Schering/Merck Ready For Vytorin; Lipid Market Growth Returns
Statin Studies May Dampen Enthusiasm For Cost-Effectiveness Trials – AARP
Zetia/Zocor Market Will Be First-Line Patients, Not Switches, Merck Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS044360

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel